Steven Seyedin, MD
Radiation Oncology · San Francisco, CANPI 1134513450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,098 and has fallen 57.0% since, to $472 in 2025.
Across 17 payments — averaging $102.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflexion Medical, Inc.$322
- Exelixis Inc.$311
- Pfizer$250
- Merck$247
- AstraZeneca$217
- Teleflex LLC$189
- plus $214 from 5 others
Across 3 payments — averaging $68,074 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$204K
What the payments were for
- Food & beverage$1,751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reflexion Medical, Inc. | 2 | $322 |
| Exelixis Inc. | 2 | $311 |
| Pfizer | 2 | $250 |
| Merck | 3 | $247 |
| AstraZeneca | 2 | $217 |
| Teleflex LLC | 1 | $189 |
| AVEO Pharmaceuticals, Inc. | 1 | $103 |
| Telix Pharmaceuticals | 1 | $36 |
| Eisai Inc. | 1 | $35 |
| Boston Scientific | 1 | $25 |
| Novocure Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,751 in reported general payments places this provider in the 70th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $1,524 |
| Tamsulosin Hcl | 62 | $866 |
| Solifenacin Succinate | 19 | $301 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in San Francisco
- Felix FengSan Francisco$99K
- David KornguthSan Francisco$46K
- Steve BraunsteinSan Francisco$41K
- I Chow HsuSan Francisco$13K
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.